Citation: | YU Na, LIU Yu-na, BAI Xiao-ling, . Adverse events following immunization among the elderly having booster COVID-19 vaccine: an active surveillance in Guiyang city[J]. Chinese Journal of Public Health, 2022, 38(9): 1113-1117. doi: 10.11847/zgggws1139515 |
[1] |
Shivalkar S, Pingali MS, Verma A, et al. Outbreak of COVID-19: a detailed overview and its consequences[M]//Asea AAA, Kaur P. Coronavirus Therapeutics – Volume II: Clinical Management and Public Health. Cham: Springer, 2021: 23 – 45.
|
[2] |
Ciotti M, Ciccozzi M, Pieri M, et al. The COVID - 19 pandemic: viral variants and vaccine efficacy[J]. Critical Reviews in Clinical Laboratory Sciences, 2022, 59(1): 66 – 75. doi: 10.1080/10408363.2021.1979462
|
[3] |
Israel A, Shenhar Y, Green I, et al. Large - scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS - CoV - 2 infection[J]. Vaccines, 2022, 10(1): 64.
|
[4] |
吕晓亚, 宋磊, 马昭, 等. 新型冠状病毒疫苗免疫策略的强化和优化[J]. 上海交通大学学报(医学版), 2021, 41(12): 1545 – 1550.
|
[5] |
Pande P, Tendolkar VD, Bankar N. COVID - 19 is dangereous for old age person[J]. Journal of Critical Reviews, 2020, 7(10): 48 – 50.
|
[6] |
北京商报. 60岁以上老年人接种新冠疫苗覆盖人数达2亿3231.1万人[EB/OL]. (2022 – 06 – 24)[2022 – 06 – 24]. https://www.sohu.com/a/560576080_115865.
|
[7] |
陈鹏, 李春辉, 郝凤, 等. 烟台市18岁及以上人群新冠疫苗加强免疫接种意愿调查[J]. 现代预防医学, 2022, 49(4): 738 – 741.
|
[8] |
卫生部办公厅, 国家食品药品监督管理局办公室. 关于印发《全国疑似预防接种异常反应监测方案》的通知[R]. 北京: 卫生部办公厅, 国家食品药品监督管理局办公室, 2010: 44 – 55.
|
[9] |
张丽娜, 李克莉, 杜雯, 等. 2019年中国疑似预防接种异常反应监测[J]. 中国疫苗和免疫, 2021, 27(4): 438 – 445. doi: 10.19914/j.CJVI.2021075
|
[10] |
武文娣, 李克莉, 许涤沙, 等. 中国2015 — 2018年3个流感季节流感疫苗疑似预防接种异常反应监测数据分析[J]. 中华预防医学杂志, 2019, 53(10): 987 – 992.
|
[11] |
Jeon M, Kim J, Oh CE, et al. Adverse events following immuniza-tion associated with the first and second doses of the ChAdOx1 nCoV - 19 vaccine among healthcare workers in Korea[J]. Vaccines, 2021, 9(10): 1096. doi: 10.3390/vaccines9101096
|
[12] |
Kant A, Jansen J, van Balveren L, et al. Description of frequencies of reported adverse events following immunization among four different COVID - 19 vaccine brands[J]. Drug Safety, 2022, 45(4): 319 – 331. doi: 10.1007/s40264-022-01151-w
|
[13] |
Tran VN, Nguyen HA, Le TTA, et al. Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021[J]. Vaccine, 2021, 39(44): 6485 – 6491. doi: 10.1016/j.vaccine.2021.09.060
|
[14] |
Supangat, Sakinah EN, Nugraha MY, et al. COVID - 19 vaccines programs: adverse events following immunization (AEFI) among medical clerkship student in Jember, Indonesia[J]. BMC Pharmac-ology and Toxicology, 2021, 22(1): 58. doi: 10.1186/s40360-021-00528-4
|
[15] |
Choi YY, Kim MK, Kwon HC, et al. Safety monitoring after the BNT162b2 COVID - 19 vaccine among adults aged 75 years or older[J]. Journal of Korean Medical Science, 2021, 36(45): e318. doi: 10.3346/jkms.2021.36.e318
|
[16] |
Chakraborty A, Reval N, Kamath L. Adverse events following COVID - 19 vaccination in selected apartments in Bangalore, India[J]. Cureus, 2022, 14(2): e21809.
|
[17] |
Wen F, Guo JY, Li ZL, et al. Sex - specific patterns of gene expression following influenza vaccination[J]. Scientific Reports, 2018, 8(1): 13517. doi: 10.1038/s41598-018-31999-x
|
[18] |
Jiang N, Gu PF, Sun X, et al. Acceptance of COVID-19 vaccines in patients with chronic diseases: a cross-sectional study[J]. Journal of Clinical Nursing, 2022, doi: 10.1111/jocn.16284.
|
[19] |
容志, 秦浩. 再组织化与社会治理现代化: 重大公共卫生事件中社区“整体网格”的运行逻辑及其启示[J]. 上海行政学院学报, 2020, 21(6): 66 – 77. doi: 10.3969/j.issn.1009-3176.2020.06.007
|
[20] |
Zhu FC, Jin PF, Zhu T, et al. Safety and immunogenicity of a recombinant adenovirus type - 5 - vectored coronavirus disease 2019 (COVID - 19) vaccine with a homologous prime - boost regimen in healthy participants aged ≥ 6 years: a randomized, double - blind, placebo - controlled, phase 2b trial[J]. Clinical Infectious Diseases, 2021: ciab845. doi: 10.1093/cid/ciab845
|
[21] |
Zhao ZX, Cui TT, Huang MZ, et al. Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants[J]. Emerging Microbes and Infections, 2022, 11(1): 829 – 840. doi: 10.1080/22221751.2022.2048969
|